An analysis of the diaminopyrimidine patent estates describing spleen tyrosine kinase inhibitors by Rigel and Portola

Author： Moore William J Richard David Thorarensen Atli

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.20, Iss.12, 2010-12, pp. : 1703-1722

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Spleen tyrosine kinase inhibitors: a review of the patent literature 2010 – 2013

By Norman Peter

Expert Opinion on Therapeutic Patents, Vol. 24, Iss. 5, 2014-05 ,pp. : 573-595

Informa Healthcare

Access to resources Recommend Favorite

Role of Spleen Tyrosine Kinase Inhibitors in the Management of Rheumatoid Arthritis

By Scott David L.

Drugs, Vol. 71, Iss. 9, 2011-06 ,pp. : 1121-1132

Adis International

Access to resources Recommend Favorite

Structure-based Drugs Design Studies on Spleen Tyrosine Kinase Inhibitors

Letters in Drug Design & Discovery, Vol. 13, Iss. 9, 2016-11 ,pp. : 845-858

Bentham Science Publishers

Access to resources Recommend Favorite

FMS-like tyrosine kinase 3 inhibitors: a patent review

By Lee Jongkook Paek Seung-Mann Han Sun-Young

Expert Opinion on Therapeutic Patents, Vol. 21, Iss. 4, 2011-04 ,pp. : 483-503

Informa Healthcare

Access to resources Recommend Favorite

Selective tyrosine kinase inhibitors

By Wilkinson S.E. Harris W.

Expert Opinion on Emerging Drugs, Vol. 5, Iss. 3, 2000-10 ,pp. : 287-297

Informa Healthcare

Access to resources Recommend Favorite